{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.1","upperLimit":"19.6","value":"3.8"},{"comment":"Lower and upper limit not calculated due to insufficient number of events","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"0"},{"groupId":"OG002","lowerLimit":"1.2","upperLimit":"15.7","value":"5.7"},{"groupId":"OG003","lowerLimit":"1.3","upperLimit":"17.5","value":"6.4"},{"groupId":"OG004","lowerLimit":"2.3","upperLimit":"28.2","value":"10.7"},{"comment":"Lower and upper limit not calculated due to insufficient number of events","groupId":"OG005","lowerLimit":"NA","upperLimit":"NA","value":"0"},{"groupId":"OG006","lowerLimit":"1.5","upperLimit":"36.4","value":"11.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"13"},{"groupId":"OG002","value":"53"},{"groupId":"OG003","value":"47"},{"groupId":"OG004","value":"28"},{"groupId":"OG005","value":"14"},{"groupId":"OG006","value":"17"}],"units":"Participants"}],"description":"Tumor response was based on Investigator assessment according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 for solid tumors (NSCLC, HCC, NET, and HRPBC), International Working Group Criteria (IWC) for DLBCL, and the International Myeloma Working Group (IMWG) criteria for MM. For GBM, Responses Assessment for Neuro-Oncology Working Group (RANO) criteria were used for tumor response, using the post resection MRI scan as the baseline. Overall Response Rate is defined as the percentage of participants with a best overall response of complete response or partial response. Complete response is defined as the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\<10 mm. Partial response is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with NSCLC received CC-223 at a starting dose of 45 mg/day (reduced to 30 mg/day after protocol Amendment 9) orally once a day in 28-day cycles for as long as they derived benefit from treatment as judged by the investigator.","id":"OG000","title":"Part B: Non-small Cell Lung Cancer (NSCLC)"},{"description":"Participants with GBM received CC-223 at a starting dose of 45 mg/day (reduced to 30 mg/day after protocol Amendment 9) orally once a day in 28-day cycles for as long as they derived benefit from treatment as judged by the investigator.","id":"OG001","title":"Part B: Glioblastoma Multiforme (GBM)"},{"description":"Participants with HCC received CC-223 at a starting dose of 45 mg/day (reduced to 30 mg/day after protocol Amendment 9) orally once a day in 28-day cycles for as long as they derived benefit from treatment as judged by the investigator.","id":"OG002","title":"Part B: Hepatocellular Carcinoma (HCC)"},{"description":"Participants with NET received CC-223 at a starting dose of 45 mg/day (reduced to 30 mg/day after protocol Amendment 9) orally once a day in 28-day cycles for as long as they derived benefit from treatment as judged by the investigator.","id":"OG003","title":"Part B: Neuroendocrine Tumor (NET)"},{"description":"Participants with DLBCL received CC-223 at a starting dose of 45 mg/day (reduced to 30 mg/day after protocol Amendment 9) orally once a day in 28-day cycles for as long as they derived benefit from treatment as judged by the investigator.","id":"OG004","title":"Part B: Diffuse Large B-cell Lymphoma (DLBCL)"},{"description":"Participants with MM received CC-223 at a starting dose of 45 mg/day (reduced to 30 mg/day after protocol Amendment 9) orally once a day in 28-day cycles for as long as they derived benefit from treatment as judged by the investigator.","id":"OG005","title":"Part B: Multiple Myeloma (MM)"},{"description":"Participants with HRPBC received CC-223 at a starting dose of 45 mg/day (reduced to 30 mg/day after protocol Amendment 9) orally once a day in 28-day cycles for as long as they derived benefit from treatment as judged by the investigator.","id":"OG006","title":"Part B: Hormone Receptor Positive Breast Cancer (HRPBC)"}],"paramType":"NUMBER","populationDescription":"Participants who received treatment in Part B reported by tumor cohort","reportingStatus":"POSTED","timeFrame":"From first dose up to tumor response (approximately 36 months)","title":"Part B: Overall Response Rate","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}